| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1146/ANNUREV.MED.53.082901.103853 |
| P698 | PubMed publication ID | 11818480 |
| P50 | author | Michael O'Dwyer | Q56447633 |
| Brian Druker | Q373427 | ||
| P2093 | author name string | Michael J Mauro | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 369-381 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Annual Review of Medicine | Q567363 |
| P1476 | title | Recent advancements in the treatment of chronic myelogenous leukemia | |
| P478 | volume | 53 |
| Q38342295 | Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells. |
| Q53724655 | Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients. |
| Q34778071 | Chromosome-mediated alterations of the MYC gene in human cancer. |
| Q28474737 | Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia |
| Q40507972 | Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. |
| Q47291002 | Cytogenetic testing for therapeutic indication in cancer |
| Q33892278 | Drug resistance in cancer: principles of emergence and prevention |
| Q28469312 | Effect of cellular quiescence on the success of targeted CML therapy |
| Q44544392 | Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium |
| Q34387503 | Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. |
| Q35104353 | High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia |
| Q35926907 | How and when should we monitor chimerism after allogeneic stem cell transplantation? |
| Q40408492 | Identification of TopBP1 as a c-Abl-interacting protein and a repressor for c-Abl expression |
| Q40515641 | Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes |
| Q39329007 | MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). |
| Q73287799 | Mutations of c‐kit at exons 17/13 are rare but clinically relevant in human subjects |
| Q78317063 | Recent publications in hematology oncology |
| Q44976586 | Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). |
| Q38861342 | Targeting eradication of chronic myeloid leukemia using chimeric oncolytic adenovirus to drive IL-24 expression |
| Q34123610 | The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire |
| Q35208824 | The RAS signal transduction pathway and its role in radiation sensitivity |
| Q46592038 | The worst drug rule revisited: mathematical modeling of cyclic cancer treatments |
| Q45026390 | Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis |
| Q43159083 | Use of oncolytic viruses for the eradication of drug-resistant cancer cells |
| Q44665745 | Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy |
| Q37052262 | alpha-Actinin interacts with rapsyn in agrin-stimulated AChR clustering |
Search more.